310 related articles for article (PubMed ID: 33677711)
1. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
Qin YZ; Jiang Q; Jiang H; Lai YY; Shi HX; Chen WM; Yu L; Huang XJ
Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
[TBL] [Abstract][Full Text] [Related]
4. Optimal Response in a Patient With CML Expressing
Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
[TBL] [Abstract][Full Text] [Related]
5. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
[TBL] [Abstract][Full Text] [Related]
6. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
7. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
[TBL] [Abstract][Full Text] [Related]
8. Detection and Clinical Implications of a Novel
Stella S; Massimino M; Tirrò E; Vitale SR; Accurso V; Puma A; Pennisi MS; DI Gregorio S; Romano C; DI Raimondo F; Siragusa S; Manzella L
Anticancer Res; 2019 Dec; 39(12):6965-6971. PubMed ID: 31810968
[TBL] [Abstract][Full Text] [Related]
9. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
Togitani K; Asagiri T; Kamioka M; Kojima K
Rinsho Ketsueki; 2021; 62(3):180-185. PubMed ID: 33828011
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3
Massimino M; Stella S; Tirrò E; Consoli ML; Pennisi MS; Puma A; Vitale SR; Romano C; Zammit V; Stagno F; DI Raimondo F; Manzella L
Anticancer Res; 2019 Jul; 39(7):3949-3954. PubMed ID: 31262926
[TBL] [Abstract][Full Text] [Related]
11. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Koren-Michowitz M; Shimoni A; Daraio F; Crasto F; Lorenzatti R; Volchek Y; Amariglio N; Gottardi E; Saglio G; Nagler A
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1852-5. PubMed ID: 26151304
[TBL] [Abstract][Full Text] [Related]
12. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
13. Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.
Limsuwanachot N; Kongruang A; Rerkamnuaychoke B; Singdong R; Niparuck P; Jootar S; Siriboonpiputtana T
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2003-2012. PubMed ID: 32711426
[TBL] [Abstract][Full Text] [Related]
14. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
[TBL] [Abstract][Full Text] [Related]
15. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.
Burmeister T; Reinhardt R
Leuk Res; 2008 Apr; 32(4):579-85. PubMed ID: 17928051
[TBL] [Abstract][Full Text] [Related]
16. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
Ercaliskan A; Eskazan AE
Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
[TBL] [Abstract][Full Text] [Related]
18. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.
Stuckey R; Casado LF; Colomer D; Gómez-Casares MT; Casas L; García-Gutierrez V; Sastre JL; Ramírez-Payer Á; Vall-Llovera F; Goñi MÁ; Xicoy B; Godoy AC; Núñez J; Mora I; Vallansot R; López-Lorenzo JL; Palomera L; Conesa V; Noya MS; Sánchez-Guijo F; Peña A; Bautista G; Steegmann JL
J Mol Diagn; 2020 Oct; 22(10):1217-1224. PubMed ID: 32688056
[TBL] [Abstract][Full Text] [Related]
19. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
Arora R; Press RD
Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
[TBL] [Abstract][Full Text] [Related]
20. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]